M1002
Modify Date: 2024-01-11 12:11:09
M1002 structure
|
Common Name | M1002 | ||
|---|---|---|---|---|
| CAS Number | 823830-85-9 | Molecular Weight | 394.292 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 414.6±55.0 °C at 760 mmHg | |
| Molecular Formula | C15H8F6N2O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 204.6±31.5 °C | |
Use of M1002M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors[1]. |
| Name | N-[3,5-Bis(trifluoromethyl)phenyl]-1,2-benzothiazol-3-amine 1,1-dioxide |
|---|---|
| Synonym | More Synonyms |
| Description | M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors[1]. |
|---|---|
| Related Catalog | |
| In Vitro | M1002 (10 μM; 24 h) enhances the expression of HIF-2 target genes with great efficacy[1]. M1002 (5 μM; 24 h) treatment shows synergy with prolyl hydroxylase domain (PHD) inhibitors[1]. RT-PCR[1] Cell Line: 786-O cells Concentration: 10 μM Incubation Time: 24 hours Result: Showed clear agonistic effects on the expression of HIF-2 target genes in 786-O cells as compared with the control. RT-PCR[1] Cell Line: Hep3B cells Concentration: 5 μM Incubation Time: 24 hours Result: Elevated the expression of EPO and NDRG1 by co-treatment of M1002 together with PHD inhibitors, compared with M1002 alone treatment. |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 414.6±55.0 °C at 760 mmHg |
| Molecular Formula | C15H8F6N2O2S |
| Molecular Weight | 394.292 |
| Flash Point | 204.6±31.5 °C |
| Exact Mass | 394.021057 |
| LogP | 5.15 |
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
| Index of Refraction | 1.564 |
| 1,2-Benzisothiazol-3-amine, N-[3,5-bis(trifluoromethyl)phenyl]-, 1,1-dioxide |
| MFCD05999002 |
| N-[3,5-Bis(trifluoromethyl)phenyl]-1,2-benzothiazol-3-amine 1,1-dioxide |